CCL23 (Chemokine (C-C motif) ligand 23), also known as MIP-3 (macrophage inflammatory protein-3), is a small cytokine belonging to the CC chemokine family. It is primarily produced by monocytes, macrophages, and dendritic cells under inflammatory conditions. CCL23 interacts with chemokine receptors CCR1 and CCR2. playing roles in leukocyte recruitment, immune regulation, and inflammatory responses. Its involvement in chronic inflammatory diseases, cancer progression, and autoimmune disorders has drawn significant research interest.
CCL23/MIP-3 antibodies are immunological tools designed to detect, quantify, or neutralize this chemokine in experimental and clinical settings. These antibodies are typically monoclonal or polyclonal, developed for applications like ELISA, Western blotting, immunohistochemistry, and flow cytometry. Neutralizing antibodies specifically block CCL23-receptor interactions, offering potential therapeutic strategies for diseases driven by aberrant chemokine signaling. Recent studies highlight their utility in investigating CCL23's role in tumor microenvironment modulation, neutrophil activation, and inflammatory cascades. While most applications remain preclinical, CCL23 antibodies are increasingly explored as diagnostic biomarkers and targeted therapy candidates, particularly in conditions like rheumatoid arthritis, atherosclerosis, and certain cancers. Their specificity and functional versatility make them valuable for both mechanistic studies and translational research.